文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌新辅助化疗:4周期与3周期对病理缓解和生存的影响

Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival.
PubMed 文献 · J Urol · 2021-08-27

该多中心回顾性研究对比肌层浸润性膀胱癌患者接受4周期与3周期顺铂为基础新辅助化疗后的ypT0率和生存,发现3周期与4周期的病理缓解和短期生存相似,非标准方案患者生存较差,毒性导致治疗调整常见。

要点

  • 3周期与4周期顺铂新辅助化疗的ypT0率和≤ypT1率无统计学显著差异。
  • 非标准新辅助化疗(1-2周期或非顺铂)患者病理缓解率和生存更低。
  • 毒性导致治疗调整常见,因毒性仅完成3周期者病理缓解似更高但未达统计学显著。

核心结论

  • 完成3周期顺铂为基础新辅助化疗的患者与4周期相比,病理缓解和短期生存相似。
  • 非标准新辅助化疗患者病理缓解率和Kaplan-Meier生存更低。
  • 因毒性仅完成3周期者的病理缓解似更高,但未达统计学显著,需进一步评估毒性作为肿瘤化疗敏感标志。

研究设计与样本

  • 多中心回顾性队列研究,纳入2个机构接受新辅助化疗后行根治性膀胱切除术的cT2-4N0M0尿路上皮癌患者。
  • 共693例患者,其中318例(45.9%)接受新辅助化疗。
  • 主要分组为4周期顺铂方案(157例)、3周期顺铂方案(114例)和非标准方案(47例,1-2周期或非顺铂),另设未接受新辅助化疗的病理参照队列。

主要发现

  • 4周期组ypT0率为42/157(26.8%),≤ypT1率为86/157(54.8%)。
  • 3周期组ypT0率为38/114(33.3%),≤ypT1率为71/114(62.3%)。
  • 非标准方案组ypT0率为6/47(12.8%),≤ypT1率为13/47(27.7%),组间比较p=0.03和p<0.01。
  • 因毒性仅完成3周期者ypT0率为29/77(37.7%),≤ypT1率为51/77(66.2%),但未达统计学显著。
  • 4周期与3周期生存无统计学显著差异(HR 1.00 [95% CI 0.57-1.74],p=0.99);非标准方案患者Kaplan-Meier生存较低(cT2-cT4N0M0:log-rank p=0.07;cT2N0M0:log-rank p=0.02)。

关键数值与推荐

  • 导致治疗调整的毒性包括血小板减少(32.1%)、中性粒细胞减少(27.2%)、肾功能不全(22.2%)和全身症状(18.5%)。
  • 4周期与3周期顺铂新辅助化疗的生存HR为1.00(95% CI 0.57-1.74),p=0.99。
  • 非标准方案与标准周期组间的ypT0率比较p=0.03,≤ypT1率比较p<0.01。

临床怎么用

  • 肌层浸润性膀胱癌患者完成3周期顺铂为基础新辅助化疗可获得与4周期相似的病理缓解和短期生存。
  • 因毒性提前终止于3周期者仍可能有较好病理缓解,不应简单视为治疗不足。
  • 非标准新辅助化疗方案(1-2周期或非顺铂)与较差病理缓解和生存相关,应尽量避免。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 非标准方案组样本量较小(47例)。
  • 因毒性仅完成3周期者的病理缓解优势未达统计学显著,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The ideal number of neoadjuvant chemotherapy (NAC) cycles for muscle-invasive bladder cancer is uncertain with 3 to 4 representing the standard of care (SOC). We compared ypT0 rates and survival between patients receiving 4 versus 3 cycles of NAC with evaluation of chemotherapy-related toxicity for correlation with tumor chemosensitivity and pathological response. MATERIALS AND METHODS: Patients receiving NAC followed by radical cystectomy for cT2-4N0M0 urothelial carcinoma from 2 institutions were included. Primary study groups included 4 cisplatin-based NAC cycles, 3 cisplatin-based NAC cycles, and nonSOC NAC (1-2 cycles or noncisplatin-based) to compare ypT0/≤ypT1 rates and survival. A cohort of patients not receiving NAC was included for pathological reference. RESULTS: Of 693 total patients, 318 (45.9%) received NAC. ypT0 and ≤ypT1 rates were 42/157 (26.8%) and 86/157 (54.8%) for 4 cycles, 38/114 (33.3%) and 71/114 (62.3%) for 3 cycles, and 6/47 (12.8%) and 13/47 (27.7%) for nonSOC (p=0.03 and p <0.01, respectively). Pathological response appeared higher among patients receiving 3 cycles due to toxicity (ypT0: 29/77 [37.7%]; ≤ypT1: 51/77 [66.2%]) but did not reach statistical significance. Toxicities leading to treatment modifications were thrombocytopenia (32.1%), neutropenia (27.2%), renal insufficiency (22.2%), and constitutional symptoms (18.5%). NonSOC patients had lower Kaplan-Meier survival (cT2-cT4N0M0: log-rank p=0.07; cT2N0M0: log-rank p=0.02). There were no statistically significant differences in survival between 4 and 3 cycles (HR 1.00 [95% CI 0.57-1.74], p=0.99). CONCLUSIONS: Patients completing 3 cycles of cisplatin-based NAC have similar pathologic response and short-term survival compared to 4 cycles. Further evaluation of patients experiencing toxicity as a potential marker of tumor chemosensitivity is needed.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Patel HD, Patel SH, Blanco-Martinez E, et al. Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival. J Urol. 2021. PMID: 34445890. doi:10.1097/JU.0000000000002189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。